Batisse et al, 2020, France | Case series (N=11), Age range=19–91 | 4/11 (36.4%) mild condition, 7/11 (63.6%) severe | 4/11 (36.4%) mild condition, 7/11 (63.6%) severe; 6/7 (85.7%) of severe cases had comorbidities | 7–14 for mild cases (4/11), 4–27 for severe cases (7/11) | 7/11 (62.6%) | 3/11 (27.3%) fatalities: 2 died of ARDS recurrence, 1 from worsening chronic right-heart failure; 3/11 developed no antibodies >21 days after severe symptoms |
Ye et al, 2020, China | 5/55 (9.1%), Age range=22–67 | 5/5 (100%) severe condition | 5/5 (100%) mild to moderate condition | 4–17 | 0/5 (0%) | No fatalities or development of severe pneumonia |
Loconsole et al, 2020, Italy | Case report, Age 48 | 1/1 (100%) severe condition | 1/1 (100%) severe condition | 31 | 0/1 (0%) | No fatality, patient remains on anticoagulation therapy; only IgG antibodies detected during 2nd episode |
Ravioli et al, 2020, Switzerland | Case reports (n=2), Age range=77–81 | 2/2 (100%) severe condition | 2/2 (100%) severe condition | 25 (patient 1) & 19 (patient 2) | 2/2 (100%) | 1/2 (50%) fatality, 1/2 (50%) hospitalized in COVID-19 isolation ward |
Qiao et al, 2020, China | 1/15 (6.7%), Age 30 | 1/1 (100%) severe condition | 1/1 (100%) moderate condition | 15 | Not Reported | No fatality |
Mei et al, 2020, China | 23/651 (3.5%), Age range=27–89 | 12/23 (52.2%) moderate condition, 9/23 (39.1%) severe, 2/23 (8.7%) critical | 15/23 (65.2%) asymptomatic, 8/23 (34.8%) mild to moderate condition | 4–38 | 1/23 (4.3%) | 2/23 (8.7%) fatalities from coronary disease and lung disease, 1/23 (4.3%) had cardiac arrest, 5/23 (21.7%) continue isolation and care |
Deng et al, 2020, China | 61/576 (10.6%), Age range=≤29–79 | 38/61 (62.3%) mild condition, 20/61 (32.8%) moderate, 3/61 (4.9%) severe | 38/61 (62.3%) asymptomatic. 23/61 (37.7%) mild to moderate condition | Not Reported | 24/61 (39.3%) | 22/61 (36.1%) remained hospitalized |
Yuan et al, 2020, China | 25/172 (14.5%), Age range=≤14–60 | 25/25 (100%) mild to moderate condition | 25/25 (100%) mild condition | 7.32 ± 3.86 | Not Reported | No fatalities |
Lafaie et al, 2020, France | Case reports (n=3), Age range=84–90 | 3/3 (100%) severe condition | 3/3 (100%) severe condition | 12->30 | 3/3 (100%) | 3/3 (100%) fatalities |